Modulim Announces Seasoned Medical Device Executive Charles Huiner as Chief Executive Officer
Modulim Announces Seasoned Medical Device Executive Charles Huiner as Chief Executive Officer
Modulim, the global leader in optical imaging solutions for the non-invasive assessment of tissue and vascular health, today announced that Charles Huiner has been named President and Chief Executive Officer (CEO). Huiner will start immediately and lead the Company's Series C fundraising and execution of a focused growth strategy for its FDA-cleared product, Clarifi®.
用於組織和血管健康非侵入性評估的光學成像解決方案的全球領導者Modulim今天宣佈，Charles Huiner被任命爲總裁兼首席執行官（CEO）。Huiner將立即開始並領導公司的C輪融資，並執行其經美國食品藥品管理局批准的產品Clarifi® 的有針對性的增長戰略。
Huiner brings over 25 years of executive experience with a successful leadership track record across multiple life science market segments including biotech, medical devices, and digital health. Most recently, he served as Chief Operating Officer and Senior Vice President, Corporate Development and Strategy for Sientra, Inc. (NASDAQ:SIEN), a global medical aesthetics company with annual revenues exceeding $80 million. While serving at Sientra, he authored the company's growth strategy, led several key acquisitions, and helped execute $375 million in equity financing including a successful IPO. Prior to that, he was Vice President of Marketing and Business Development at InTouch Health during a transformative period that solidified the company's market strategy and commercial model, leading to its eventual $600 million exit to Teladoc Health. Previously, as Senior Director of Corporate Development and Strategy at INAMED, Inc. he was instrumental in broadening the company's product portfolio that contributed to its $3.3 billion acquisition by Allergan Aesthetics.
Huiner 擁有超過 25 年的高管經驗，在包括生物技術、醫療設備和數字健康在內的多個生命科學市場領域擁有成功的領導記錄。最近，他曾擔任首席運營官兼企業發展和戰略高級副總裁 Sientra, Inc.。納斯達克股票代碼：SIEN），一家年收入超過8000萬美元的全球醫學美容公司。在Sientra任職期間，他制定了公司的增長戰略，領導了幾項重要收購，並幫助執行了3.75億美元的股權融資，包括成功的首次公開募股。在此之前，他在變革時期擔任InTouch Health的營銷和業務發展副總裁，這鞏固了公司的市場戰略和商業模式，最終使其以6億美元退出 Teladoc 健康。此前，他曾在INAMED, Inc.擔任企業發展和戰略高級總監，在擴大公司的產品組合方面發揮了重要作用，這促成了Allergan Aesthetics的33億美元收購。
"It's fantastic to have Charlie on-board to lead Modulim's next phase," said David Cuccia, Modulim's Founder, Board member and Chief Technology Officer. "With Charlie's experience and expertise, we are poised to build from a number of key milestones recently achieved by the Company to accelerate commercialization. The whole executive team looks forward to working with him to enact Modulim's mission—to deliver transformative optical solutions that help people live healthier, longer lives."
Modulim的創始人、董事會成員兼首席技術官戴維·庫西亞說：“讓查理加入領導Modulim的下一階段真是太棒了。”“憑藉查理的經驗和專業知識，我們準備在公司最近實現的許多關鍵里程碑的基礎上再接再厲，加速商業化。整個高管團隊期待與他合作，實現 Modulim 的使命——提供變革性的光學解決方案，幫助人們過上更健康、更長壽的生活。”
"I am excited for the opportunity to lead Modulim's talented team. The Company will play a significant role in the ongoing convergence of medical diagnostic, predictive AI, and telehealth technologies to enable more efficient healthcare delivery. Our decision support solutions are applicable to numerous ill-met chronic conditions and vascular complications, starting with helping healthcare providers prevent costly and often deadly undiagnosed conditions brought on by diabetes and peripheral arterial disease," said Huiner. "I look forward to working with my new colleagues to accelerate the adoption and expansion of our proprietary SFDI technology while improving the lives of patients."
“我很高興有機會領導 Modulim 才華橫溢的團隊。該公司將在醫療診斷、預測人工智能和遠程醫療技術的持續融合中發揮重要作用，以實現更高效的醫療保健服務。我們的決策支持解決方案適用於許多未得到滿足的慢性病和血管併發症，首先是幫助醫療保健提供者預防由糖尿病和外周動脈疾病引起的昂貴且往往是致命的未確診疾病，” Huiner說。“我期待與我的新同事合作，加快我們專有的SFDI技術的採用和擴展，同時改善患者的生活。”
"We are pleased to have attracted a high-caliber, proven executive like Charlie to strengthen the Company and advance on early successes with strategic customers," said Janelle Goulard, Partner at Pangaea Ventures. "Charlie brings extensive technology commercialization knowledge and experience at this dynamic period of growth for Modulim. We believe the Clarifi solution will positively impact millions that are living with chronic conditions."
Pangeaa Ventures合夥人珍妮爾·古拉德表示：“我們很高興吸引了像查理這樣高素質、久經考驗的高管，以加強公司實力，在戰略客戶中取得早期成功。”“在Modulim這個充滿活力的增長時期，查理帶來了豐富的技術商業化知識和經驗。我們相信，Clarifi解決方案將對數百萬患有慢性病的人產生積極影響。”
About Modulim
關於 Modulim
Modulim is a privately held medical device company founded by the inventors of SFDI at the University of California Irvine with a team dedicated to delivering powerful healthcare solutions that elevate and standardize health care delivery, while improving patient outcomes. Its mission is to deliver transformative optical solutions that help people live healthier, longer lives. Clarifi, powered by Spatial Frequency Domain Imaging (SFDI) technology, identifies compromised circulation at the point of care through non-contact rapid microvascular assessment of tissue. Clinicians and healthcare systems are empowered by SFDI images to make proactive, data-driven decisions in a multidisciplinary care setting, to reduce lower-limb complications caused by diabetes and peripheral arterial disease. Clarifi Imaging System is an FDA cleared and CE Marked product. Modulim is backed by Pangaea Ventures, Fresenius Medical Care Ventures, Grey Sky Venture Partners, Mitsubishi Capital, Hamamatsu Photonics, The Cove Fund at UCI Applied Innovation, and Fouse KK.
Modulim 是一傢俬營醫療器械公司，由加州大學爾灣分校的 SFDI 發明者創立，其團隊致力於提供強大的醫療保健解決方案，提升和標準化醫療保健服務，同時改善患者預後。其使命是提供變革性的光學解決方案，幫助人們過上更健康、更長壽的生活。Clarifi 由空間頻域成像 (SFDI) 技術提供支持，通過對組織進行非接觸式快速微血管評估，在護理點識別血液循環受損。SFDI 圖像使臨床醫生和醫療保健系統能夠在多學科護理環境中做出基於數據的主動決策，從而減少糖尿病和外周動脈疾病引起的下肢併發症。Clarifi 成像系統是 FDA 批准並獲得 CE 認證的產品。Modulim 由 Pangaea Ventures、Fresenius Medical Care Ventures、Grey Sky Venture Partners、三菱資本、濱松光電、UCI 應用創新的 Cove 基金和 Fouse KK 支持。
Clarifi is a registered trademark of Modulated Imaging (dba Modulim).
Clarifi 是調製成像 (dba Modulim) 的註冊商標。
View source version on businesswire.com:https://www.businesswire.com/news/home/20201208005951/en/View Comments and Join the Discussion!
在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20201208005951/en/View 評論然後加入討論！
譯文內容由第三人軟體翻譯。